Clinical value of 3'-deoxy-3'-[18F]fluorothymidine-positron emission tomography for diagnosis, staging and assessing therapy response in lung cancer
Abstract Lung cancer has the highest mortality rate of any tumour type. The main driver of lung tumour growth and development is uncontrolled cellular proliferation. Poor patient outcomes are partly the result of the limited range of effective anti-cancer therapies available and partly due to the li...
Main Authors: | Bandar Alwadani, Sergio Dall’Angelo, Ian N. Fleming |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2021-07-01
|
Series: | Insights into Imaging |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13244-021-01026-1 |
Similar Items
-
Evaluation of the Performance of 18F-Fluorothymidine Positron Emission Tomography/Computed Tomography (18F-FLT-PET/CT) in Metastatic Brain Lesions
by: Alexandra Nikaki, et al.
Published: (2019-01-01) -
An Assessment of Early Response to Targeted Therapy via Molecular Imaging: A Pilot Study of 3′-deoxy-3′[(18)F]-Fluorothymidine Positron Emission Tomography 18F-FLT PET/CT in Prostate Adenocarcinoma
by: Kalevi Kairemo, et al.
Published: (2017-04-01) -
Diagnostic Value of 11C-Methionine (MET) and 18F-Fluorothymidine (FLT) Positron Emission Tomography in Recurrent High-Grade Gliomas; Differentiation from Treatment-Induced Tissue Necrosis
by: Takashi Tamiya, et al.
Published: (2012-03-01) -
Comparison of <sup>18</sup>F-fluorothymidine Positron Emission Tomography/Computed Tomography and <sup>18</sup>F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Patients with Breast Cancer
by: Mio Mori, et al.
Published: (2022-10-01) -
Comparison of Positron Emission Tomography Using 2-[18F]-fluoro-2-deoxy-D-glucose and 3-deoxy-3-[18F]-fluorothymidine in Lung Cancer Imaging
by: Fu-Li Wang, et al.
Published: (2016-01-01)